Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two different neoadjuvant treatment strategies for adults with muscle-invasive bladder cancer MIBC that expresses the HER2 protein. The study aims to compare disitamab vedotin RC48 combined with gemcitabine versus disitamab vedotin combined with toripalimab before surgery, focusing on the rate of complete tumor removal confirmed by pathology. This is a Phase 3 trial designed to assess if the two treatment approaches are similarly effective in this setting. Participants will be randomly assigned to one of two groups one receives disitamab vedotin plus gemcitabine, and the other receives disitamab vedotin plus toripalimab. Both treatments are given intravenously every two weeks for 3 to 6 cycles, depending on tumor response seen in imaging after the initial 3 cycles. After completing neoadjuvant therapy, all patients undergo radical cystectomy with pelvic lymph node dissection within four weeks. Those eligible will then receive additional adjuvant therapy with disitamab vedotin plus toripalimab for 6 cycles, followed by up to one year of toripalimab maintenance therapy. During the study, participants will have regular imaging scans of the abdomen, pelvis, and chest every 3 to 6 months after surgery, or cystoscopy and imaging if bladder-sparing treatment is chosen. Study staff will contact participants every 3 months to track imaging results and symptoms such as hematuria or respiratory issues, and to document any cancer recurrence or progression. The primary outcome is the pathological complete response rate measured shortly after surgery. Safety is monitored through tracking treatment-related adverse events during neoadjuvant therapy. The total study duration is up to 3 years from start to completion.
Actively Recruiting
Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.
Actively Recruiting
Researchers are evaluating a treatment for people with spontaneous supratentorial intracerebral hemorrhage ICH, a serious type of stroke caused by bleeding in the brain. The study is a phase III randomized controlled trial that will involve 768 participants to compare a new minimally invasive surgery combined with a clot-dissolving drug against standard medical care. This trial aims to assess the safety and effectiveness of using tenecteplase to liquefy and drain brain hematomas, potentially improving recovery outcomes. Participants will be randomly assigned to one of two groups. One group will receive minimally invasive stereotactic catheter placement followed by the local injection of tenecteplase to liquefy and drain the hematoma, with doses of 0.5 mg given up to four times over several days. The other group will receive standard medical treatment in line with current guidelines. The surgery uses imaging to target the hematoma, and after catheter placement, tenecteplase is carefully administered through the catheter with close monitoring. Throughout the study, participants will undergo regular assessments including neurological exams, brain imaging, and functional outcome evaluations up to 180 days after treatment. The main measurement is the modified Rankin Score assessing disability and recovery. Other outcomes include neurological improvement, hematoma size, mortality, and quality of life. Follow-up visits may be conducted face-to-face or remotely, and researchers will carefully monitor safety and treatment effects during this period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an artificial intelligence-based multimodal cognitive screening system to identify mild cognitive impairment MCI related to diabetes early in patients with type 2 diabetes mellitus T2DM. This observational study follows participants for 3 to 5 years to assess the systems accuracy and feasibility. The study also explores how diabetic metabolic indicators, such as glycemic variability and HbA1c levels, relate to changes in cognitive function, aiming to improve early detection and intervention for cognitive decline in T2DM patients. Participants are observed without additional interventions over the 3 to 5 years of follow-up. The study includes groups of participants with normal cognition and those with mild cognitive impairment. Cognitive status data are collected at the beginning and end of the study period, with no study drug or treatment administered. During the study, participants undergo cognitive assessments and monitoring of diabetic metabolic factors. Researchers measure the accuracy of the AI screening system in early detection and track the rate of cognitive decline over the follow-up period. The study also evaluates the predictive value of combining multiple types of data. Participants remain under observation with regular assessments, helping to understand the relationship between diabetes and cognitive changes over time.
Actively Recruiting
Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of TQC2731 injection in adults with severe asthma that is not adequately controlled. The study aims to compare TQC2731 with a placebo to better understand its impact on asthma exacerbations and other clinical outcomes in this population. Participants are randomly assigned in a 11 ratio to receive either TQC2731 injection or placebo via subcutaneous injection every 4 weeks. Treatment cycles last 4 weeks each, with study drug administration continuing from Day 0 up to Week 48. The trial includes two groups one receiving the active drug and the other receiving placebo, both with the same dosing schedule. During the study, participants will be monitored for asthma exacerbations, lung function through forced expiratory volume in 1 second FEV1, asthma control questionnaires, quality of life assessments, symptom diaries, and biomarker changes such as blood eosinophils and immunoglobulin E levels. Safety assessments include monitoring for anti-drug antibodies and neutralizing antibodies. The primary outcome is the annualized incidence of asthma exacerbations from the first day of dosing through 52 weeks. Secondary outcomes and safety follow-up extend up to Week 64.